FDA Guidance on Off-Label Promotion and the State of the Literature From Sponsors
- 23 April 2008
- journal article
- editorial
- Published by American Medical Association (AMA)
- Vol. 299 (16), 1949-51
- https://doi.org/10.1001/jama.299.16.1949
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Selective Publication of Antidepressant Trials and Its Influence on Apparent EfficacyNew England Journal of Medicine, 2008
- Ghost Management: How Much of the Medical Literature Is Shaped Behind the Scenes by the Pharmaceutical Industry?PLoS Medicine, 2007
- Ghost Authorship in Industry-Initiated Randomised TrialsPLoS Medicine, 2007
- Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry DocumentsAnnals of Internal Medicine, 2006
- Off-label Prescribing Among Office-Based PhysiciansArchives of Internal Medicine, 2006
- Expression of Concern: Bombardier et al., “Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis,” N Engl J Med 2000;343:1520-8.New England Journal of Medicine, 2005
- Medical Journals Are an Extension of the Marketing Arm of Pharmaceutical CompaniesPLoS Medicine, 2005
- High-Dose Statins in Acute Coronary Syndromes: Not Just Lipid Levels—CorrectionPublished by American Medical Association (AMA) ,2005